Pre-clinical studies of anti-LAG3 in lymphoma (2017–2019)

Grant type:
Bristol-Myers Squibb Pharmaceuticals Pty Limited
Funded by:
Bristol-Myers Squibb Pharmaceuticals Pty Limited